Antibodies

16 Feb 2017 XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)
16 Feb 2017 FDA approves new psoriasis drug
14 Feb 2017 Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
13 Feb 2017 MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20
13 Feb 2017 OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
11 Feb 2017 TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma
08 Feb 2017 BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
08 Feb 2017 Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
06 Feb 2017 Ablynx submits a marketing authorisation application to the European Medicines Agency for caplacizumab, its anti-vWF nanobody, for the treatment of aTTP
06 Feb 2017 Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia
03 Feb 2017 Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
03 Feb 2017 Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
02 Feb 2017 CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial
01 Feb 2017 XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
01 Feb 2017 European Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
31 Jan 2017 Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
27 Jan 2017 Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
27 Jan 2017 ImmunoGen Announces First Patient Dosed in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
26 Jan 2017 Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
26 Jan 2017 Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology
26 Jan 2017 Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-Il-17A/F (M1095) in a phase Ib clinical study in patients with psoriasis
26 Jan 2017 First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP)
25 Jan 2017 Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus Aureus Pneumonia
25 Jan 2017 AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
24 Jan 2017 FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top